Photoactivatable ion channel modulator
US-2024409594-A1 · Dec 12, 2024 · US
Methods of modulating immune responses using BCMA polypeptide
US10494416B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10494416-B2 |
| Application number | US-201715595733-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 15, 2017 |
| Priority date | Aug 17, 1999 |
| Publication date | Dec 3, 2019 |
| Grant date | Dec 3, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a B-cell lympho-proliferate disorder in a mammal, the method comprising the step of administering to the mammal an effective amount of a BCMA (B-Cell Maturation Antigen) polypeptide, wherein the BCMA polypeptide comprises an amino acid sequence that binds to BAFF (B-Cell Activating Factor of the TNF family; SEQ ID NO:9) and is: a) at least 95% identical to amino acids 1-51 of SEQ ID NO:1; or b) at least 95% identical to amino acids 8-41 of SEQ ID NO:1. 2. The method of claim 1 , wherein the BCMA polypeptide comprises an Fc domain of an immunoglobulin. 3. The method of claim 1 , wherein the mammal is human. 4. The method of claim 1 , wherein the BCMA polypeptide comprises the sequence of amino acids 1-51 of SEQ ID NO:1. 5. The method of claim 1 , wherein the BCMA polypeptide comprises the sequence of amino acids 8-41 of SEQ ID NO:1. 6. The method of claim 2 , wherein the immunoglobulin is IgG. 7. The method of claim 2 , wherein the immunoglobulin is human.
Assignees
Inventors
Classifications
- A61K38/17Primary
from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10494416B2 cover?
- A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
- Who is the assignee on this patent?
- Biogen Ma Inc, Topotarget Switzerland Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K38/17. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).